13.71
Schlusskurs vom Vortag:
$13.44
Offen:
$13.57
24-Stunden-Volumen:
1.29M
Relative Volume:
0.20
Marktkapitalisierung:
$2.55B
Einnahmen:
$93.95M
Nettoeinkommen (Verlust:
$-129.87M
KGV:
-15.23
EPS:
-0.9
Netto-Cashflow:
$-202.88M
1W Leistung:
-5.71%
1M Leistung:
+2.85%
6M Leistung:
+67.60%
1J Leistung:
+22.08%
Wave Life Sciences Ltd Stock (WVE) Company Profile
Firmenname
Wave Life Sciences Ltd
Sektor
Branche
Telefon
617-949-2900
Adresse
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
WVE
Wave Life Sciences Ltd
|
13.71 | 2.50B | 93.95M | -129.87M | -202.88M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-05 | Eingeleitet | BofA Securities | Buy |
| 2025-12-12 | Bestätigt | Wedbush | Outperform |
| 2025-12-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-28 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-16 | Eingeleitet | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Wedbush | Outperform |
| 2025-02-25 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | Fortgesetzt | JP Morgan | Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-05-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-12-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Raymond James | Outperform |
| 2023-05-24 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Market Perform |
| 2019-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2018-08-07 | Eingeleitet | Stifel | Buy |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2017-02-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-07 | Eingeleitet | Jefferies | Buy |
| 2015-12-07 | Eingeleitet | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten
FY2029 Earnings Forecast for WVE Issued By HC Wainwright - MarketBeat
Wave Life Sciences Obesity Proof Of Concept Sparks Focus On Pipeline Upside - simplywall.st
WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan
Wave Life Sciences Ltd. (WVE) Stock Analysis: Biotechnology Innovator with 140% Upside Potential - DirectorsTalk Interviews
How Strong Q4 Revenue Amid Deeper Losses At Wave Life Sciences (WVE) Has Changed Its Investment Story - Yahoo Finance
Wave Life Sciences (WVE) Earnings Call Transcript - AOL.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Reiterates "Buy" Rating for WAVE Life Sciences (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Teases Near-Term Obesity and RNA Editing Data as INLIGHT Readouts Near - Yahoo Finance
Artisan Partners Limited Partnership Trims Stake in WAVE Life Sciences Ltd. $WVE - MarketBeat
How Mixed Q4 Results, Obesity Data and Cash Runway News At Wave Life Sciences (WVE) Has Changed Its Investment Story - simplywall.st
Wave Life Sciences Ltd. (WVE): A Bull Case Theory - Finviz
Primecap Management Co. CA Has $13.90 Million Position in WAVE Life Sciences Ltd. $WVE - MarketBeat
Wave Life Sciences Ltd. (WVE) Announces Fiscal Q4 and Full-Year 2025 Earnings - Yahoo Finance
Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Insider Sells 33,194 Shares of Stock - MarketBeat
Wave Life Sciences (WVE) officer nets 33,194-share sale after option exercises - Stock Titan
WAVE Life Sciences (NASDAQ:WVE) Shares Down 10.6%What's Next? - MarketBeat
WAVE Life Sciences Q4 Earnings Call Highlights - MarketBeat
Decoding WAVE Life Sciences Ltd (WVE): A Strategic SWOT Insight - GuruFocus
Wave Life Sciences (WVE) Quarterly Loss Deepens Bear Narratives On Profitability And Cash Burn - simplywall.st
Wave Life Sciences: Q4 Earnings Snapshot - theheraldreview.com
WAVE Life Sciences Ltd (WVE) Q4 2025 Earnings Call Highlights: N - GuruFocus
Wave Life Sciences at Oppenheimer Conference: Strategic Insights on RNA Medicines - Investing.com Australia
Wave Life Sciences (WVE) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Wave Life Sciences Posts Wider FY25 Loss, Highlights Progress Across RNA Pipeline - Nasdaq
Earnings call transcript: Wave Life Sciences Q4 2025 sees revenue drop - Investing.com
Wave Life Sciences (WVE) Reports Strong Q4 Revenue and Advances in Obesity Treatment - GuruFocus
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Investing News Network
WAVE Life Sciences Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Wave Life Sciences: Fourth Quarter Financial Overview - Bitget
Wave Life Sciences Swings to Q4 Net Loss, Revenue Falls - marketscreener.com
Earnings Flash (WVE) Wave Life Sciences Posts Q4 Loss $0.30 a Share, vs. FactSet Est of $0.26 Loss - marketscreener.com
Earnings Flash (WVE) Wave Life Sciences Ltd. Reports Q4 Revenue $17.2M, vs. FactSet Est of $16.1M - marketscreener.com
WAVE LIFE SCIENCES ($WVE) Releases Q4 2025 Earnings - Quiver Quantitative
Wave Life Sciences Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
Wave Life Sciences Ltd earnings missed by $0.03, revenue topped estimates By Investing.com - Investing.com India
Wave Life Sciences Highlights 2025 Results and Obesity Progress - TipRanks
Wave Life Sciences Ltd earnings missed by $0.03, revenue topped estimates - Investing.com
Wave Life Sciences Ltd. SEC 10-K Report - TradingView
Earnings Summary: WAVE Life Sciences Q4 - Benzinga
Wave Life Sciences (NASDAQ: WVE) doubles cash, widens 2025 loss on R&D push - Stock Titan
Earnings Preview: WAVE Life Sciences - Benzinga
Investors brace for Wave Life Sciences earnings on obesity bets By Investing.com - Investing.com Canada
Wave Life Sciences Ltd. (WVE) Stock Analysis: Exploring 147% Upside In Biotech Innovation - DirectorsTalk Interviews
WAVE Life Sciences (WVE) Projected to Post Earnings on Tuesday - MarketBeat
A Look At Wave Life Sciences (WVE) Valuation After WVE-006 Rights Return And Obesity Program Spotlight - simplywall.st
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
Wave Life Sciences (WVE) Valuation Check After Regaining WVE-006 Rights And New Buy Analyst Coverage - Yahoo Finance
Is Haverty Furniture Companies Inc stock a buy or sell2025 Year in Review & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Merger Talk: Is Wave Life Sciences Ltd gaining market share2025 Growth vs Value & Safe Entry Trade Signal Reports - baoquankhu1.vn
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026 - Bitget
Finanzdaten der Wave Life Sciences Ltd-Aktie (WVE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Wave Life Sciences Ltd-Aktie (WVE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Francis Chris | See Remarks |
Feb 26 '26 |
Sale |
15.05 |
33,194 |
499,593 |
61,867 |
| Moran Kyle | Chief Financial Officer |
Feb 09 '26 |
Sale |
13.45 |
3,588 |
48,259 |
134,385 |
| BOLNO PAUL | President and CEO |
Feb 09 '26 |
Sale |
13.45 |
10,480 |
140,956 |
275,520 |
| Francis Chris | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
1,883 |
25,326 |
61,867 |
| Vargeese Chandra | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
3,228 |
43,417 |
408,246 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):